Category : Healthcare and Pharmaceuticals | Delivery Format : PDF | Status: Forthcoming | Report ID : ARC456
Introduction
Cancer metabolism refers to the changes in cellular metabolism paths that are patent in cancer cells compared with normal tissue cells. Therapeutic in medicine, is the art and science of healing and the branch that deals with the treatment of specific disease. Therapeutics accordingly refers to the method of administration in the treatment of disease and the use of drugs. According to the discovery made by Otto Warburg in the middle of 20th century, metabolic activity in cancerous tissue increases the amount of creation of lactate (from glucose) by ten-fold, under aerobic condition. This revelation had generated a major interest and led industry stakeholders to aim metabolic pathways in an effort to find curable factors of cancer. Cancer metabolism is based upon cancer cells, which alter the metabolism of glutamine and glucose for nucleotides, synthesis of lipids proteins, and fatty acid that helps to increase cancer cells. It results in inhibition of various metabolic alleyways, such as the mitochondrial respiration, glucose, glutamine utilization, and citric acid cycle. Due to the complex nature of these metabolic pathways, innovation in this domain has been gradual.
Market Dynamics
The primary focus is on drugs that lead to metabolic pathways in cancer cells by inhibiting or altering the activity of key enzymes that are a part of lactate metabolism, pentose phosphate pathway, lipid metabolism, amino acid metabolism, nucleotide metabolism and TCA cycle. Rising incidence of cancer, growth of advance therapies, and commercialization of biosimilars are the few factors driving the growth of global cancer drugs market. In addition, it includes unique products that are being exactly developed to target inhibiting metabolic pathways and key enzymes involved in the metabolism of cancer cells, are driving the market. Due to high cost involved in new drug development tied with threat of adverse effects associated with cancer drugs therapies and failure would halt the growth of market. Targeting cancer metabolism condition represents opportunity to develop unique drugs to treat multiple cancer types. Also increasing incidences of cancer is expected to boost the growth of cancer metabolism based therapeutics market.
Market Classification
The market can be segmented on the basis of drug type, therapy, indication and geography. By drug type, the cancer metabolism based therapeutics market can be segmented into CPI-613, Enasidenib, and other drugs. By therapy, the cancer metabolism based therapeutics market can be segmented into biological, and targeted drug therapies. By indication, the cancer metabolism based therapeutics market can be segmented into Acute Myeloid Leukemia (AML), Melanoma, Metastatic Renal Cell Carcinoma, and Myelodysplastic Syndromes (MDS). On the basis of geography, the cancer metabolism based therapeutics market can be segmented into North America, Latin America, Europe, Middle East & Africa (MEA) and Asia-Pacific.
Report Coverage
|
Market |
Cancer Metabolism Based Therapeutics Market |
|
Analysis Period |
2014 – 2024 |
|
Historic Data |
2014 – 2015 |
|
Base Year |
2016 |
|
Forecast Data |
2017 – 2024 |
|
Market Stratification |
Drug Type, Therapy, Indication, Geography |
|
Regional Scope |
North America, Europe, Asia-Pacific, Latin America, Middle East and Africa (MEA) |
|
Report Coverage |
Market Trends, Drivers, Restraints, Porter's Five Forces Analysis, Competitive Analysis, Player Profiling, Value Chain Analysis |
Market Participants
Some of the major players involved in the supply of cancer metabolism based therapeutics market include Polaris Group, Agios Pharmaceuticals, Bio-Cancer Treatment International, Celgene, 3-V Biosciences, Cornerstone Pharmaceuticals, BERG Health, Taiho Pharmaceutical, and Novartis , and among others.
Market Segmentation
· Market By Drug
o CPI-613
o Enasidenib
o Others
· Market By therapy
o Biological
o Targeted drug
· Market By Indication
o Acute Myeloid Leukemia (AML)
o Melanoma
o Metastatic Renal Cell Carcinoma
o Myelodysplastic Syndromes (MDS)
· Market By Geography
· North America
o U.S.
o Canada
o Mexico
· Europe
o UK
o France
o Germany
o Rest of Europe
· Asia-Pacific
o China
o Japan
o India
o Australia
o Rest of Asia-Pacific
· Latin America
o Brazil
o Chile
o Rest of LATAM
· Middle East and Africa (MEA)
o South Africa
o Saudi Arabia
o Rest of MEA
